Several crucial updates have come from Laboratory Corporation of America Holdings (LH). The company has reported quarterly and full-year results for 2024 with full-year earnings per share (EPS) missing expectations. Its SWOT analysis suggests stock resiliency despite challenging industry shifts while its Q1 earnings surpassed estimates and its fiscal year 2024 EPS forecast was raised. A new product- Plasma Complete Liquid Biopsy Test for personalized cancer care has been unveiled. Despite beating earnings and revenues, the stock fell due to declining margins. Dividends have been announced for 2025 and LH reached an 80-Plus Relative Strength Rating. Notably, LH also issued Senior Notes and expanded its credit facility to $700 million. Buy ratings were initiated by Jefferies and the stock reached a 52-week high amid robust growth. While some shares were traded, they were also acquired by different firms and a number of institutional investors. The company plans to boost mpox testing capacity. Moreover, it launched the H5 Bird Flu Test in the U.S. amid an outbreak and received an Italian nod to lucratively sell a Synlab minority stake. LH declared its robust earnings to be conservative and revealed winning bids for select Invitae assets while continuing to acquire others.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 23 Feb 2017 08:00:00 GMT to Fri, 28 Feb 2025 17:47:31 GMT - Rating 6 - Innovation 5 - Information 8 - Rumor 2
